| Ms Linde A Schuster, MSCCCSLP | |
|
1210 N 1st St, Raton, NM 87740-3500 | |
| (505) 445-5184 | |
| (505) 445-5184 |
| Full Name | Ms Linde A Schuster |
|---|---|
| Gender | Female |
| Speciality | Qualified Speech Language Pathologist |
| Experience | 37 Years |
| Location | 1210 N 1st St, Raton, New Mexico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891997326 | NPI | - | NPPES |
| 585 | Other | NM | SLP LICENCE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 585 (New Mexico) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Huerfano County Hospital District | 4789591769 | 26 |
News Archive
Nearly a decade after federal officials discarded a provision in the Affordable Care Act that would have provided Americans with long-term care insurance benefits, two states — Washington and Hawaii — are experimenting with taxpayer-funded plans to help older residents remain in their homes.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.
Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus - 4 of which also exhibited neutralizing activity - within 4 days, according to a new study.
Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen.
AIDS Healthcare Foundation (AHF) lauded Gilead Sciences, maker of several key AIDS drugs, for its announcement earlier today that it will offer significant pricing and access concessions for the nation's beleaguered AIDS Drug Assistance Programs (ADAPs), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need.
› Verified 9 days ago
| Provider Name | Huerfano County Hospital District |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1982612065 PECOS PAC ID: 4789591769 Enrollment ID: O20040202001045 |
News Archive
Nearly a decade after federal officials discarded a provision in the Affordable Care Act that would have provided Americans with long-term care insurance benefits, two states — Washington and Hawaii — are experimenting with taxpayer-funded plans to help older residents remain in their homes.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.
Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus - 4 of which also exhibited neutralizing activity - within 4 days, according to a new study.
Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen.
AIDS Healthcare Foundation (AHF) lauded Gilead Sciences, maker of several key AIDS drugs, for its announcement earlier today that it will offer significant pricing and access concessions for the nation's beleaguered AIDS Drug Assistance Programs (ADAPs), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Linde A Schuster, MSCCCSLP Po Box 525, Raton, NM 87740-0525 Ph: (505) 445-5184 | Ms Linde A Schuster, MSCCCSLP 1210 N 1st St, Raton, NM 87740-3500 Ph: (505) 445-5184 |
News Archive
Nearly a decade after federal officials discarded a provision in the Affordable Care Act that would have provided Americans with long-term care insurance benefits, two states — Washington and Hawaii — are experimenting with taxpayer-funded plans to help older residents remain in their homes.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.
Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus - 4 of which also exhibited neutralizing activity - within 4 days, according to a new study.
Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen.
AIDS Healthcare Foundation (AHF) lauded Gilead Sciences, maker of several key AIDS drugs, for its announcement earlier today that it will offer significant pricing and access concessions for the nation's beleaguered AIDS Drug Assistance Programs (ADAPs), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need.
› Verified 9 days ago
Ms. Anne Marie Walton, MA CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 North Second St, Raton, NM 87740 Phone: 505-445-7090 | |
Mrs. Amy Dianne Bennett, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1535 Tiger Cir, Raton, NM 87740 Phone: 575-445-3541 | |
Mrs. Anita Beth Wright, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 N 2nd St, Raton, NM 87740 Phone: 505-445-7090 | |
Mrs. Keely E. Aragon-horton, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 N 2nd St, Raton, NM 87740 Phone: 505-445-7090 Fax: 505-447-7663 | |
Sara Eliason, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 726 Apache Ave Apt 1, Raton, NM 87740 Phone: 505-334-3695 | |
Jena Lee Love, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1535 Tiger Cir, Raton, NM 87740 Phone: 505-445-9111 |